The isolation and characterization of renal cancer initiating cells from human Wilms' tumour xenografts unveils new therapeutic targets†
Pode‐Shakked N, Shukrun R, Mark‐Danieli M, Tsvetkov P, Bahar S, Pri‐Chen S, Goldstein RS, Rom‐Gross E, Mor Y, Fridman E, Meir K, Simon A, Magister M, Kaminski N, Goldmacher VS, Harari‐Steinberg O, Dekel B. The isolation and characterization of renal cancer initiating cells from human Wilms' tumour xenografts unveils new therapeutic targets†. EMBO Molecular Medicine 2012, 5: 18-37. PMID: 23239665, PMCID: PMC3569651, DOI: 10.1002/emmm.201201516.Peer-Reviewed Original ResearchMeSH KeywordsAC133 AntigenAldehyde DehydrogenaseAldehyde Dehydrogenase 1 FamilyAnimalsAntibodies, MonoclonalAntigens, CDCD56 AntigenCell DifferentiationCell ProliferationCell SeparationGene ExpressionGlycoproteinsHumansKidney NeoplasmsMaytansineMiceMice, Inbred NODMice, SCIDNeoplastic Stem CellsPeptidesRetinal DehydrogenaseTumor Cells, CulturedTumor Stem Cell AssayWilms TumorXenograft Model Antitumor AssaysConceptsNew therapeutic targetsTherapeutic targetPediatric solid tumorsPoor patient prognosisCancer initiating cellsMultiple xenograft modelsHuman WilmsCancer stem cellsAldehyde dehydrogenase activityMiR-200 familyPrimary tumorPatient prognosisRenal malignancyImmunodeficient micePediatric cancerXenograft modelTumor xenograftsXenograft cellsSolid tumorsTumor biologyComplete eradicationPediatric renal malignancyInitiating cellsProtein expressionTumorsFirst-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
Sen M, Thomas SM, Kim S, Yeh JI, Ferris RL, Johnson JT, Duvvuri U, Lee J, Sahu N, Joyce S, Freilino ML, Shi H, Li C, Ly D, Rapireddy S, Etter JP, Li PK, Wang L, Chiosea S, Seethala RR, Gooding WE, Chen X, Kaminski N, Pandit K, Johnson DE, Grandis JR. First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy. Cancer Discovery 2012, 2: 694-705. PMID: 22719020, PMCID: PMC3668699, DOI: 10.1158/2159-8290.cd-12-0191.Peer-Reviewed Original ResearchConceptsSTAT3 target genesTarget genesSTAT3 target gene expressionSTAT3-selective inhibitorsTarget gene expressionInhibited xenograft growthSelective STAT3 inhibitorSystemic administrationTranscription factor decoyTranscription factorsSTAT3 proteinBroader clinical developmentGene expressionPhase 0 trialsSTAT3 inhibitorHuman cancersSTAT3Expression levelsSTAT3 decoyCancer cellsCellular viabilityNeck cancerSaline controlsNeck tumorsHuman trials